Trial Profile
A Randomised, Double-Blinded, Placebo-Controlled Trial of Lamivudine Treatment in HBeAg Negative Chronic Hepatitis B Patients (in Asia)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 30 Aug 2023
Price :
$35
*
At a glance
- Drugs Lamivudine (Primary)
- Indications Hepatitis B
- Focus Therapeutic Use
- 02 Jul 2015 New trial record